Arecor Ltd is celebrating its 10th year and to mark the occasion it is holding a 40Km and 80Km charity cycle ride, raising funds and awareness for the JDRF organisation.
Arecor team cycles for charity to celebrate its 10th anniversary
The team says:
We are proud to be fundraising for this fantastic charity which funds research, campaigns, gives support and raises awareness of Type 1 Diabetes.
The event will take place on Friday 4th August 2017 with a team of Arecor staff cycling either the 40Km or the 80Km route. All staff will be involved on the day, either cycling or marshalling the route and providing motivation and support along the way!
Please offer your support to our team by visiting our dedicated JustGiving page to make a donation:
Thank you for your support
About Arecor Limited
Arecor Ltd is a Cambridge-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides enabling the improved treatment of diabetes and other conditions. Arecor is currently leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
- Stable aqueous glucagon for emergency and artificial pancreas use,
- Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
- Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices.
In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Its mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since their inception.
On 25 July 2016, JDRF announced that it had partnered with Arecor to advance the pre-clinical trials of Arecor’s ultra-concentrated insulin. The goal of the partnership is to accelerate the development of a stable, rapid-acting, ultra-concentrated insulin of up to 1,000 U/mL, which will not only offer a vastly superior mealtime insulin product for people requiring >200 U/day, but is also a critical step towards the advancement of the miniaturization of delivery devices, including next-generation artificial pancreas systems for people with type 1 diabetes.
JDRF are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. They collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. JDRF’s staff and volunteers throughout the United States and their six international affiliates are dedicated to advocacy, community engagement and their vision of a world without T1D. For more information, please visit: www.jdrf.org or follow them on Twitter: @JDRF
About severe hypoglycaemia
Severe Hypoglycaemia is an acute, life threatening emergency condition resulting from a significant drop in blood sugar levels and is an ever-present risk for type I and type 2 diabetics who are on insulin therapy. To treat this condition, glucagon must be administered to restore ‘normal’ blood sugar levels and glycemic control. Severe hypoglycaemia is a common problem for people living with diabetes with approximately 20% of type 1 patients experiencing at least one severe hypoglycaemic event annually. The American Diabetes Association (ADA) recommends that all patients with type 1 and type 2 diabetes on insulin therapy carry a glucagon kit with them at all times [Center for Disease Control and Prevention 2011].
About glucagon and current gold standard glucagon rescue treatments
Glucagon is a metabolic hormone secreted by the pancreas, which plays an important role in the control of blood sugar levels helping to release stored glucose into the blood stream to increase blood sugar levels. Administration of therapeutic glucagon as a rescue treatment for severe hypoglycaemia is safe and effective, however, its use is challenging due to the peptide’s low solubility and very poor stability in liquid solution. Thus, currently available glucagon
treatments (rescue kits) are only available in the form of a lyophilized or freeze-dried powder, which requires the caregiver to perform a complex multi-step reconstitution procedure prior to administration. Under this highly stressful situation, the reconstitution procedure can and does lead to handling errors and delayed administration of glucagon, resulting in sub-optimal treatment. This is a significant barrier to the use of these rescue kits with recent usability studies demonstrating that more than 80% of people failed to reconstitute properly and inject the recommended dose of glucagon. As a result, only 10-20% of high-risk patients own a glucagon emergency kit.
Arecor’s proprietary stable and ready-to-inject liquid glucagon has the potential to significantly de-risk and simplify the administration of this life-saving treatment with an estimated 25million insulin users worldwide (Source: International Diabetes Federation, Diabetes Atlas, 2015)
Advancing today's therapies to enable healthier lives.